Table 1

Characteristics of study participants at baseline and 8 weeks

Placebo (n=19)Omega-3 (n=19)
Baseline8 weeksChange (%)Baseline8 weeksChange (%)
Age (years)45 (33–52)45 (27–52)
Weight (kg)91 (74–117)91 (74–115)0.0±0.491 (69–115)91 (68–115)0.1±0.5
BMI (kg/m2)27.6 (22.0–35.1)27.8 (21.6–34.6)0.0±0.428.9 (24.6–34.6)28.7 (24.1–34.8)0.1±0.5
Waist (cm)100 (86–116)99 (87–114)0.9±0.499 (94–121)99 (92–122)−1.0±0.7
Hip (cm)103 (93–113)103 (94–113)0.0±0.3104 (94–121)104 (92–123)0.2±0.6
HOMA-IR3.2±0.33.3±0.32.9±6.13.5±0.33.5±0.28.8±6.2
Fasting plasma biochemical parameters
Glucose (mmol/L)5.4±0.15.5±0.11.9±2.05.5±0.15.7±0.1*4.2±2.0
Insulin (mU/L)13.4±1.013.2±1.00.3±5.014.1±1.114.1±0.83.9±5.4
NEFA (µmol/L)388±30389±336.6±12.0371±30346±30−2.7±7.4
Total cholesterol (mmol/L)5.6±0.25.5±0.2−0.2±5.55.7±0.25.6±0.2−0.4±3.7
HDL cholesterol (mmol/L)1.23±0.061.24±0.050.5±2.41.02±0.041.03±0.033.5±4.2
Non-HDL cholesterol (mmol/L)4.6±0.24.2±0.2−3.3±7.74.7±0.24.5±0.2−1.1±3.4
TAG (mmol/L)2.2±0.22.2±0.22.8±7.72.2±0.21.7±0.2**−18.1±6.7†
3OHB (µmol/L)51±961±839±3254±950±64±9
ALT (IU/L)32±232±23.9±6.536±426±2**−16.6±6.6†
Erythrocytefatty acids(mol%)
EPA (20:5 n-3)1.1±0.11.1±0.1−1.4±3.41.0±0.12.9±0.2***224±32‡‡‡
DPA (22:5 n-3)5.7±0.25.6±0.2−0.8±1.35.7±0.16.0±0.2**4.7±1.6†
DHA (22:6 n-3)8.3±0.38.2±0.3−1.8±1.28.4±0.29.5±0.3***12.4±1.9‡‡‡
  • Data expressed as median (min–max) or mean±SEM. Change (%) expressed as mean±SEM.

  • *P<0.05, **p<0.01, ***p<0.001 baseline vs 8 weeks within the group.

  • ‡P<0.05, ‡‡p<0.01, ‡‡‡p<0.001% change in placebo vs omega-3 group.

  • ALT, alanine transaminase; BMI, body mass index; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; HDL, high density lipoprotein; HOMA-IR, homeostatic model assessment of insulin resistance; NEFA, nonesterified fatty acids; 3OHB, 3-hydroxybutyrate; TAG, triacylglycerol.